Presentation and composition

Tabets:Yellow scorew unccated stamped”Searle on one side each containing dimenhydrinate B. P. 50 mg .

Loquid:Cherry flavoured each 4ml containing Dimenhydrinate B.P.12.mg.

Ampoules:1 ml ampoules each containing Dimenhydrinate B.P. 50mg.

Lndlations:Prevention and relief and motion sickness and treatment of vertigo nausea or vomiting associated with: electroshock therapy anaesthesia and surgery labyrinthine disturbances radiation sickess and postfenestration syndrome.DosGE Oral children 4ml of Gravinate liquid contains 12.5mg of Dimenhydrinate. The liquid dosage form is recommended for children. For children 5mg/kg daily in 2 or 3 divided doses is recommended.Children: 2-6 years 12.5-25 mg (4-8 ml ) 2to 3 times daily 6-12 years 25-50 mg (8-16ml) 2to3timmes daily or use as directed by the physician.

Contralndlcatlons:Hypersensitivity to the active ingredient epilepsy infants and children under 5 years of age to increased susceptibility to anticholinergic agents and their effects (CNS  excitation and increased tendency toward convulsions) narrowangle glaucoma prostatic hypertrophy urinary retention severe hepatic function impairmebt.

Precautions and warnings:Patients should be warned to inform physician of use and report promptly any occurring gastrointestinal disturbances during administration because of risk of developing paralytic  ileus and impaired diagnosis of appendicitis. It should not be administered to children under 5and to patients in advanced age. It may mask the symptoms of toxicity of other medication. It may inhibit the cutaneous histamine response in skin tests using allergen extracts and produce falsenegative results therefore its use should be discontinued at least 27 h before testing.

Pregnancy and breast feeding:It should not be used during  the first trimester of pregnancy and during breast feeding it may inhidit lactation due to its anticholinergic activity. Excreted amounts in breast milk may cause inceased excitability irritability and sensitization in the breast fed infant.

Side effects:Signs and symptoms of hypersensitivity skin rash stomach upset and pain tiredness weaknss drowsiness dryness of mouth blurred vision which are transient or decrease after  dose reduction and may be prevented by concurrent use of caffeine.

Fil coated tablets/Oral solution

Propertles:

Antiallergic agent; Allergic reaction inhibitor. In experimental animais,cetirzine exhibits an anti-h1 activity without any significant anticholin. Ergic and antiserotonin effects. At pharmacologically active doses, cetirizine induces neither sedation nor dehavioral modifications. Cetirizine nor behavioral modifications. Cetirizine exhibits a powerful and iasting  anfagonisic effect particularly selective at the level of the H1- receptors. In human pharmacology, its periheral activity is demonstrated by the clearly sihnificant  inhibition of:

1-the immediate wheal and flare reaction induced by intracutaneous injection of histamine.

2- the endogenous histamine released in viva as a result of stimulation by 48/80

3- the immediate allergic skin reaction triggered by an intracutaneous injection of pollen.

4- the oedmatous sikn reaction induced by substance p or VIP(vasoactive intestinal polypeptide).

5- the immediate allergic nasal reaction triggred by instillation of an allergen.

These effect are achieved without any central effect  being objectively demonstrated neither by psychometric tests nor by duantifieb EEG. A 10 mg intake of cetirizine produces a blood peak of about 0.3/uh/ml between the30 Th and 60 Th minutes. Lts plasma half- life- time is approximare-ly 11hours. It should be noted that resorption is very regular in every subject. Its renal clerance is 30mi/min and the half- excretion time is about 9 hours.

Pregnancy and lactation:

Teratological studies carried out in animals did not evidence any particular malformation. However, as a precaution cetirizine should not be administered to pregnant women during the perod of organ

ogenesis. The same applies to lactation period.

Interactions:

No interaction has been reported so far.

Storage:

Store at room temperature.

Protect from light freezing and excessive heat.

Stability:

Check whether the expiry date on the packaging after the word, Exp, has nos not passed.

peptinil Tablets & suspension

Absorption and fate ranitidine is readily absorbed from the gastro-intestinal tract with peak plasma concentration achieved in about 2 hours after oral administration. A small proportion of  Ranitidine is metabolized in the liver approximately 30 of the oral dose is excreted in the urine in 24 hours. Ranitidine crosses the placental barrier and is excreted in breast milk where concentrations are reported to be higher than those in plasma. it does not readily cross blood brain barrier. Indiations and usual dosage: duodenal and gastric ulcers: A single dose of peptinil  D.S.(Ranitdine 300 mg) one tablet once daily at bedtime or PEPTINIL (Ranitine 150mg) one tablet twice daily (in the mominh and at bed time) is recommendeb for at least four weeks. A dose of  PEPTINIL D.S.(ranitidine 300mg) onetablet tablet twice daily may also be used. where appropriate PEPTINIL(ranitidine 150 mg) one tablet may be given as maintenance dose at bedtime

prophylactic with nsaids:
PEPTINIL(Ranitine 150 mg) one tablet twice daily is given with non-steroidal anti influx esophagitis: PEPTINIL(Ranitidine 150 mg) one tablet is given twice daily for eight weeks.
POSSIBLE ADVERSE REACTIONS:
the incidence of adverse reactions is low however headache,dizziness, nausea, vomiting, diarrhea, constpation & skin reactins have been reported.
precautins: store in a cool dry and dark placa between 15 to 30 cto peptinil D S tablets& between 15-25/cto peptinil tablets.
PRESENTATIONS:
peptinil 150 mg &peptinil D.S.300mg tablets are available in blister of 10's, packing containing 10 tablets Pepin 75 mg /5ml suspension is available in bottle containing60 ml approx.